Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
RAPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.67 - $26.56
Previous CloseN/A
Volume421.15K
Average Volume (3M)107.17K
Market Cap
$167.01M
Enterprise Value$87.36M
Total Cash (Recent Filing)$179.28M
Total Debt (Recent Filing)$3.83M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Nov 06, 2025EPS Estimate
-1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding16,536,085
10 Day Avg. Volume51,476
30 Day Avg. Volume107,168
Financial Highlights & Ratios
PEG Ratio-0.86
Price to Book (P/B)2.71
Price to Sales (P/S)0.00
P/FCF Ratio-6.18
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-286.42
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$23.67Price Target Upside130.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Drug EfficacyRPT904 demonstrated a 60-day half-life at 150 mg vs 26 days for omalizumab at 150 mg, indicating potential for broader applicability and potential for at least comparable efficacy with less frequent dosing.
Financial PerformanceRAPT reported better than expected net loss per share, which was ($0.08) versus the consensus of ($0.14).
Market OpportunityFood Allergy is a massive market opportunity, and even an incremental share can result in a potentially large blockbuster opportunity for the company.
Bears Say
Clinical TrialsA setback in the Jemincare’s phase 2 study in CSU and asthma could call into question the potential success of RPT904.
Data TimelinesThe Neutral rating on RAPT shares balances the de-risked mechanism and significant potential of lead asset RPT904 in Food Allergy and Chronic Spontaneous Urticaria with prolonged timelines to company-sponsored data in key indications.
Market SentimentRAPT shares are likely to be a sentiment underperformer until RAPT flips its own cards for RPT904.
RAPT Therapeutics News
RAPT FAQ
What was RAPT Therapeutics’s price range in the past 12 months?
RAPT Therapeutics lowest stock price was $5.67 and its highest was $26.56 in the past 12 months.
What is RAPT Therapeutics’s market cap?
RAPT Therapeutics’s market cap is $167.01M.
When is RAPT Therapeutics’s upcoming earnings report date?
RAPT Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.
How were RAPT Therapeutics’s earnings last quarter?
RAPT Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.711 by $0.061.
Is RAPT Therapeutics overvalued?
According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued.
Does RAPT Therapeutics pay dividends?
RAPT Therapeutics does not currently pay dividends.
What is RAPT Therapeutics’s EPS estimate?
RAPT Therapeutics’s EPS estimate is -1.03.
How many shares outstanding does RAPT Therapeutics have?
RAPT Therapeutics has 16,536,085 shares outstanding.
What happened to RAPT Therapeutics’s price movement after its last earnings report?
RAPT Therapeutics reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.711. Following the earnings report the stock price went up 2.603%.
Which hedge fund is a major shareholder of RAPT Therapeutics?
Currently, no hedge funds are holding shares in RAPT
RAPT Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.67 (130.93% Upside)
$23.67 (130.93% Upside)
Blogger Sentiment
Bullish
RAPT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 182.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 20.3%
Last 30 Days ▲ 20.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.69%
12-Months-Change
Fundamentals
Return on Equity
-77.83%
Trailing 12-Months
Asset Growth
20.38%
Trailing 12-Months
Company Description
RAPT Therapeutics
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Stock 12 Month Forecast
Average Price Target
$23.67
▲(130.93% Upside)
Technical Analysis
Ownership Overview
1.61% Insiders
3.75% Mutual Funds
85.22% Other Institutional Investors
3.67% Public Companies and
Individual Investors